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Abstract
Objective: We assessed the prognostic value of histomorphologic features of lymph node (LN) metastases in patients with prostate cancer treated with radical prostatectomy
Materials and Methods: We evaluated the effect of the features of LN metastasis on the risk of biochemical recurrence (BCR) in 280
LN-positive patients who underwent radical prostatectomy between 2006 to 2018. LN specific parameters recorded included number of
metastatic LNs, size of the largest metastatic focus, Gleason Grade (GG) of the metastatic focus, and extranodal extension (ENE).
Results: A solitary positive LN was found in 166/280 (59%), 95/280 (34%) patients had 2-4 positive LNs, and 19/280 (7%) had 5 or
more positive LNs. The size of the largest metastatic focus > 2 mm (macrometastasis) in 154/261 (59%). GG of the metastatic focus was as
follows: GG 1-2: 29/224 (13%); GG 3: 27/224 (12%); and GG 4-5: 168/224 (75%). ENE was identified in 99/244 (41%). We found the
number of LNs positive (2-4 vs. 1 Hazard ratio (HR) = 1.60; 95% CI: 1.02 to 2.5; P = 0.04) and GG of the metastatic focus (GG 4&5 vs. 1-3
HR = 1.90; 95% CI: 1.14-3.2; P= 0.014) to be independent predictors of the risk of BCR after surgery on multivariate analysis.
Conclusions: Our study showed the number of LNs positive and GG of the LN metastatic focus to be significant independent predictors
of BCR after radical prostatectomy. We recommend reporting histomorphologic parameters of LN metastasis as they may help in defining
BCR risk categorization. Ó 2021 Elsevier Inc. All rights reserved.
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1. Introduction

This research did not receive any specific grant from funding agencies in
the public, commercial, or not-for-profit sectors.
Previous Presentation: This work was presented, in part, at the United
States and Canadian Academy of Pathology 108th Annual Meeting,
National Harbor, MD, March 16-21, 2019, and at the American Urological
Association 114th Annual Meeting, Chicago, IL, May 3-6, 2019.
*Corresponding author. Tel: 313-916-2353; Fax: 313-916-2385
E-mail address: NGUPTA1@hfhs.org (N. Gupta).

The prognosis of patients with prostate cancer showing
lymph node (LN) metastasis at radical prostatectomy is variable [1,2]. Various easily recordable histomorphologic features, e.g., the number of positive LN, the size of metastatic
focus, the presence of extranodal extension (ENE), and
grade group (GG) of metastatic focus, identified within
these positive LN might explain some of this variability in
outcome. Moreover, in recent years, the adoption of the

https://doi.org/10.1016/j.urolonc.2021.03.018
1078-1439/Ó 2021 Elsevier Inc. All rights reserved.
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surgical extended pelvic LN dissection has resulted in an
increase in the rate of detection of LN metastasis [3],
including occult metastases [4], which otherwise would
have gone undetected. Therefore, risk stratification by LN
features has been proposed to improve the management of
these patients and potentially spare those with favorable
features the side effects of unnecessary adjuvant treatment
[5].
Several prior studies [5-9] have shown variable association of these histomorphologic features with the outcome of
cancer treatment, and the predictive value of these features
has remained controversial. Hence the current version of
American Joint Committee on Cancer system [10] does not
currently take into account the number of these features and
only substratifies the patients into LN negative (pN0) and
LN positive (pN1). We aimed to determine the prognostic
value of histomorphologic features of lymph node (LN)
metastases in patients with prostate cancer treated with radical prostatectomy
2. Material and Methods
The Institutional Review Board approved this study at
Henry Ford Hospital. We reviewed all node positive robotassisted radical prostatectomy cases between 2006 and
2018. Cases with prior neoadjuvant therapy or cases with
known metastasis at the time of surgery were excluded.
In every case, the prostate gland and the LN specimens
were entirely submitted for microscopic evaluation. GG of
the dominant tumor nodule, pathologic stage, margin status,
and tumor volume were recorded. Clinical information
about biochemical recurrence (BCR) was collected using
serum prostate-specific antigen based on American Urological Association guidelines (biochemical recurrence
defined as an initial PSA value = 0.2 ng/mL followed by a
subsequent confirmatory PSA value = 0.2 ng/mL) [11].

Fig. 1. Size of the entire positive lymph node was recorded (arrow).
(Hematoxylin and eosin stain, 2X magnification).

The size of positive LN: This parameter refers to the overall size of the LN with the largest metastatic focus (Fig. 1).
The size of the largest metastatic focus: The size of the
single largest metastatic focus was recorded in a linear,
two-dimensional fashion. The presence of minute metastatic focus up to 2 mm was labeled as micrometastasis,
similar to some of the other organ sites such as breast and
endometrium, and > 2 mm metastasis was labeled as macrometastasis (Fig. 2).
The GG of metastatic focus: Although grading of prostate cancer is not recommended outside of prostate, we
found a wide spectrum of grades in metastatic foci. Hence,
we used GG to assess the differentiation of the metastasis,
the same way it is currently used in prostatic cancer (Fig. 3).
Extranodal extension: Defined as unequivocal tumor
perforation of the LN capsule into the surrounding pericapsular adipose tissue (Fig. 4).
2.2. Statistical analysis

2.1. LN recorded pathologic features
The number of positive LNs: For statistical analysis, we
grouped the number of positive LNs into 3 categories: 1, 24, and 5 or more LN.

The association between positive LN features and BCR
was examined using Kaplan-Meier curves (log-rank test)
and multivariate analysis using Cox proportional hazards
model by R software.

Fig. 2. Size of the largest metastatic focus. A. minute focus or micrometastasis (0.1-2 mm) and B. >2 mm metastasis or macrometastasis. (Hematoxylin and
eosin stain).
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Fig. 3. Examples of different grade groups. A. Grade group 1, B. grade group 2, C. grade group 4, and D. grade group 5 (Hematoxylin and eosin stain A-C:
20X magnification, D: 4X magnification).

3. Results
We identified a total of 280 patients after excluding 18
cases with neoadjuvant therapy and 2 with LN metastases
diagnosed before surgery. The median age was 64 years old
(range 41-83). The pathologic findings collected from the

Fig. 4. The tumor invades through the lymph node capsule and extends to
the pericapsular adipose tissue (arrow) (Hematoxylin and eosin stain, 10X
magnification).

prostate and the LN dissection are illustrated in Tables 1
and 2.
The median number of LN retrieved was 13 (range 142). A solitary positive LN was found in 166/280 (59%),
95/280 (34%) patients had 2-4 positive LNs, and 19/280
(7%) had 5 or more positive LNs. The median size of the
largest metastatic focus was 3 mm (range 0.1-65). Twothirds of our cohort (167/234) had largest positive LN measuring less than or equal to 1 cm in size, and 107/261 (41%)
cases only comprised of micrometastatic foci (< 2 mm),
either single or multiple. Interestingly, 94/107 (88%) cases
of the micrometastasis (< 2 mm) cases had involvement of
only a single LN and around 20% of which had ENE. However, it is important to indicate that these minute metastatic
foci involved tiny LNs, which in many cases did not show a
well formed capsule, were predominantly fatty and any
involvement by the tumor resulted in spreading into the adipose tissue. ENE positive LNs was equal to or less than
10 mm in 87% of the cases.
The follow-up period ranged from 1.5 to 100 months
(median 7 months). BCR developed in 155 (55%) patients.
On univariable analysis, The number of positive LNs was
significantly associated with BCR (p < 0.001; Fig. 5A).
BCR increased as the number of LN metastasis increased.
Forty-one percent of our cohort of high-risk patients had
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Table 1
Radical prostatectomy data (grade group, pathologic stage, surgical margins, and tumor volume) in 280 patients found to have lymph node metastasis after radical prostatectomy
Pathologic variable
Grade group of the prostate
2
2 with minor pattern 5
3
3 with minor pattern 5
4
5
Pathological stage (pT)
T2
T3a
T3b
T4
Surgical margins
Negative
Positive
Tumor volume
1%-14%
15%-49%
50%-100%

N (%) (n = 280)

30 (11%)
13 (5%)
34 (12%)
45 (16%)
36 (13%)
122 (44%)
11 (4%)
98 (35%)
170 (61%)
1 (0.4%)
128 (46%)
152 (54%)
65 (23%)
155 (55%)
60 (21%)

micrometastasis (up to 2 mm). The latter was associated
with lower BCR rates compared to metastatic focus of >
2 mm in size (macrometastasis) (P < 0.001; Fig. 5B).
The vast majority of patients (75% of the cases) had GG
4 and 5 within the LN. Most foci of metastatic prostate cancer were present as cohesive cribriform clusters, solid nests,
or sheets even when the primary tumor in the prostate was
predominantly formed by discohesive single cells. The differentiation of prostate cancer within the LNs was significantly associated with BCR (P = 0.001; Fig. 5C). The GG
Table 2
Lymph node data (number of positive lymph node(s), size of largest metastatic focus, grade group of metastases, presence of extranodal extension,
and unilateral vs. bilateral involvement) in 280 patients found to have
lymph node metastasis after radical prostatectomy.
Pathologic variable
Number of positive lymph node(s)
1
2-4
≥5
Size of largest metastatic focus (n=261)
Micrometastasis (up to 2mm)
Macrometastasis (>2 mm):
Grade group of lymph node metastasis (n=224)
1 -3
4&5
Extranodal extension (n=244)
Negative
Positive
Unilateral and bilateral involvement (n=273)
Unilateral
Bilateral

N (%) (n=280)

166 (59%)
95 (34%)
19 (7%)
107 (41%)
154 (59%)
56 (25%)
168 (75%)
145 (60%)
99 (40%)
198 (73%)
75 (27%)

of LN metastasis matched the GG of the prostate in only
40% of the patients. The GG of the primary tumor was
lower than the GG of the LN metastasis in 33% and higher
than the GG of the LNs in 27%.
Most LNs (60%) were negative for ENE, and the presence of ENE was significantly associated with BCR
(P = 0.02; Fig. 5D). Unilateral LN involvement was seen in
almost three-fourths of our cases. However, no difference
was observed between unilateral and bilateral involvement
(P = 0.09).
We also analyzed patient group with solitary micrometastasis and no ENE (n = 71, 25% of our cohort). These
“favorable group,” of patients had a significantly lower rate
of BCR compared to the “unfavorable group,” (P < 0.001)
who had more than 1 LN metastasis, metastatic focus more
than 2 mm, and ENE. Similar analysis was also done for
patients with negative resection margins (n = 37), and it did
not show significant difference in BCR rates between the
two groups (P = 0.06).
From our multivariable analysis, two features of LN
metastasis were independently associated with BCR in our
cohort: Higher number of positive LNs was associated with
BCR (2-4 vs. 1 Hazard ratio (HR) = 1.60; 95% CI: 1.02-2.5;
P = 0.04). In addition, GG of the metastatic focus was an
independent predictor of the risk of BCR (GG 4&5 vs. 1-3
HR = 1.90; 95% CI: 1.14-3.2; P = 0.014) (Table 3).
4. Discussion
LN status is a crucial prognostic indicator in cancer in
general. In prostate cancer, it is well understood that the
presence of LN metastasis after radical prostatectomy is not
uniformly associated with poor prognosis [5]. The current
American Joint Committee on Cancer TNM staging do not
stratify the LN stage based on the extent of LN involvement
and merely categorizes all patients with positive LN into a
single pN1 category [12]. Table 4 highlights a few studies
published in the English literature that have studied different LN features and have found that some of these features
are significant and independent predictors of outcome and
overall prognosis.
Passoni et al., in a study including 484 patients with
prostate cancer, found that patients with 1 or 2 positive LNs
have better survival rates than men with ≥ 3 LN metastases.
In their multivariable analysis, the diameter of the largest
LN metastasis and the dichotomised number of positive
LNs were independent predictors of early BCR. At the
same time, ENE did not reach statistical significance as an
independent predictor. Overall, they found that patients
with ≥ 3 positive LNs have 2.7 times the probability of having early BCR than men with 1 or 2 positive LNs [5]. In
another study, Briganti et al looked at cancer specific survival (CSS) in 703 LN positive patients treated with radical
prostatectomy and extended pelvic LN dissection between
1988 and 2003 at two large academic institutions. The
authors found that the number of positive nodes represents
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a key variable for CSS predictions. Patients with up to 2
positive nodes in this cohort had an excellent CSS rate,
which was significantly higher compared to patients with
more than 2 positive nodes (P< 0.001). The authors concluded that these results reinforce the need for stratification
of node positive patients according to the number of positive nodes proposing a revision of the pathologic TNM
classification [13]. In our study, we were also able to demonstrate a difference in BCR rates between patients with
solitary positive LN vs. multiple positive LNs. Single LN
involvement was seen in the majority (59%) of our cases, in
spite of our cohort consisting of more advanced prostate
cancer within the prostate gland with 57% of cases

5

belonging to Gleason score 8-10 compared to only 29.5%
in the Briganti et al. study and 44% in the Passoni et al.
study.
In another study, Fleischmann et al. looked at 102 prostate cancer patients with positive LN metastasis, the author
concluded that the presence of ENE in node positive
prostate cancer is an indicator lesion for more aggressive
disease; however, the only independent prognostic information they found was the size of largest tumor metastasis [8].
The same author in another study [14] looked at survival
in patients with LN positive prostate cancer, and their
results showed that substaging is possible in LN positive
prostate cancer, which is in contrast to the current TNM

Fig. 5. Kaplan-Meier plots of BCR by A. number of positive lymph node(s), B. size of largest metastatic focus, C. grade group of metastatic focus, D. presence of extranodal extension.
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Fig. 5.. Continued

classifications. In this study, the authors found that higher
nodal tumor burden, ENE, and less differentiated primary
tumor and LN metastases are more likely to experience an
adverse outcome. They proposed using the size of the largest metastases of 10 mm as a cut-off for substaging basing
their suggestion on the fact that the largest metastasis size
showed independent prognostic value, and it is simple to
assess. In our study, 87% of LN metastasis were 10 mm or
smaller with a median size of 3 mm compared to 73% with
a median size of 6 mm in their study. Their median LN
count was 21, which was much higher than our median of
13. We evaluated the entire LN packets microscopically for
possible LNs. The differences in the LN yield are perhaps
attributable to either difference in LN counting methodology, the extent of LN dissection by the urologists, or differences in yield between robotic and non-robotic surgical
techniques. The size of the largest metastatic focus was

significantly associated with BCR but did not reach statistical significance as an independent predictor of BCR in our
study.
Another suggestion from Fleischmann et al. was to use
the category “micrometastasis only,” because of its favorable prognosis [14]. In our study, a large cohort of patients
(94 patients, 88%) within solitary metastasis group showed
micrometastasis. Our findings support their conclusion, as
our analysis showed that patients with micrometastasis (up
to 2 mm) are associated with lower BCR rates compared to
metastatic foci >2 mm in size (macrometastasis). Interestingly, we showed that patients who belonged to the favorable group (1 LN metastasis, micrometastasis, and no
ENE), constituting 25% of our patients, had far better outcomes in terms of BCR as opposed to patients in the unfavorable group. This finding is in keeping with the literature
that showed that patients with a single LN metastasis had
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Table 3
Results of the multivariate analysis of predictors of biochemical recurrence
after prostatectomy in patients with lymph node metastasis
Variable

Hazard ratio
(95% confidence interval)

Primary tumor characteristics
Grade group of the prostate
2
Reference
3
2.03 (0.90-4.62)
4
4.26 (1.79-10.15)
5
3.74 (1.65-8.49)
Pathological stage (pT)
T2
Reference
T3a
1.62 (0.49-5.40)
T3b and T4
1.70 (0.52-5.65)
Surgical Margins
Negative
Reference
Positive
1.35 (0.91-1.99)
Histopathologic features of lymph node metastasis
Number of positive lymph
nodes
1
Reference
2-4
1.6 (1.02-2.5)
≥5
2.4 (1.15-5.1)
Size of largest metastatic
focus
Micrometastasis (≤ 2 mm)
Reference
Macrometastasis (> 2mm)
1.3(0.79-2.1)
Grade group of lymph node
metastasis
1-3
Reference
4&5
1.9 (1.14-3.2)
Extra nodal extension
Negative
Reference
Positive
1.30 (0.85-2.00)

P value

0.09
0.001*
0.002*

0.43
0.38

0.14

0.04*
0.02*

0.32

0.014*

0.50

* significant predictor of biochemical recurrence after radical prostatectomy.

favorable prognosis [2,15]. Potentially instead of relying on
a single histomorphologic criterion, such as size or number
of positive LNs, patients with LN metastasis may need further stratification based on all of these features into two

7

(favorable or unfavorable) or more categories. This stratification should be further explored in multiple larger studies
in relationship to BCR, disease specific survival, and overall survival.
While grading of tumors at the metastatic sites is not
very common in pathology, prostate cancer is unique in the
sense that the grading is entirely based on architectural patterns and not related to cytologic features. Multiple grading
tiers compared to tumors arising from other organ sites
makes it easy to recognize the change in the differentiation
of prostate cancer within the LN metastasis. Very few studies have explored the significance of grading prostatic adenocarcinoma within the LNs or other metastatic sites.
Boormans et al. looked at CSS in 146 patients with confirmed LN positive prostate cancer, the two only independent predictors of clinical outcomes were nodal Gleason
score and diameter of the largest metastasis. The presence
of nodal Gleason score of > 7 and a diameter of the largest
metastasis of > 3 mm was correlated with poor CSS [9].
Our study supports their findings, and we were able to demonstrate that GG of metastasis is an independent predictor
of BCR.
Sub-centimeter LNs detected on imaging in the preoperative setting are often presumed to be free of metastasis.
Our cohort had positive LNs measuring ≤ 10 mm in twothirds of our patients. This observation is essential as these
LNs (≤ 10 mm) often harbor small metastatic foci or micrometastasis and often escape detection as abnormal on
conventional imaging in the preoperative setting or by intraoperative palpation. Hence decision making for pelvic LN
dissection should be based on other preoperative risk factors, and less weight should be placed on negative imaging
characteristics. Furthermore, the standard gross dissection
protocols usually include submitting only palpable LNs for
histological examination [16], this procedure has the potential of overlooking small and impalpable LNs [6,16]. At our
center, we submit the entire LN packets, starting with

Table 4
Summary of lymph node histopathologic features studies.
Study

Year

Lymph Node Features Studied

Significant Independent Predictor

Statistical Analysis

Passoni et al. [5]

2014

Number of positive LN(s)
Size of metastatic focus

HR = 2.80; 95% CI 1.99-3.93; P = 0.001
HR = 1.48; 95% CI 1.16-1.89; P = 0.002

Luchini et al. [6]
Carlsson et al. [7]

2017
2013

ENE
Number of positive LN(s)

HR = 1.40, 95% CI 1.12-1.74; I2 = 0%
HR = 1.84; 95% CI 1.24-2.73; P = 0.002

Fleischmann et al. [8]

2008

Size of metastatic focus

HR = 2; 95% CI 1.3-3.2; P = 0.002

Boormans et al. [9]

2008

Number of positive LN(s);
Size of metastatic focus;
ENE
ENE
Number of positive LN(s);
Size of metastatic focus;
ENE
Number of positive LN(s);
Size of metastatic focus;
ENE;
Gleason score of metastasis
Number of positive LN(s);
Size of metastatic focus;
ENE;
Gleason score of metastasis

Size of metastatic focus
Gleason score of metastasis

HR = 2.173; 95% CI 1.01-4.66; P = 0.046
HR=1.85; 95% CI 1.09-3.11; P=0.021

ENE, extranodal extension; HR, hazard ratio; LN, lymph node.
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identifying palpable LNs followed by submitting the
remainder of tissue entirely. A study published from our
group looked at the effectiveness of the submission of entire
LN tissue [17], and we found that it improves the number of
LN yield by 37% and positive LN detection by 2%, hence
this protocol is critical in detecting micrometastasis.
Our study’s limitations include the following: short follow-up, BCR was the only oncologic outcome measured,
and disease specific or overall survival was not studied. The
lack of standardized postsurgical treatment with adjuvant/
anti-androgen therapy is another limitation that could not
be controlled in our study. Only 30% of our patients
received adjuvant treatment and any analysis of the effects
of adjuvant therapy on BCR would have been an under estimate of the effects of such treatment. In fact, we tested for
the effect of adjuvant treatment on BCR in our cohort of
patients and found it non-significant.
Further studies with longer follow-up periods and a more
inclusive set of cancer population may be helpful to further
substratify patients with LN metastasis in prostate cancer
and to identify patients who will require adjuvant therapy
while those who could be followed.
5. Conclusion
Our multivariable analysis showed that the the number
of positive LNs and GG of the LN metastasis are independent predictors of BCR after radical prostaetctomy. LN
metastasis can easily be stratified into favorable and unfavorable groups based on these histomorphogic features
within LN. To further evaluate the significance of our findings and the need for their incorporation into the TNM staging, larger prospective studies with longer follow-up are
needed.
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